Contacts

Patsy Folio

CONTACT

1-240-415-6022 [email protected]

Transis Clemons

CONTACT

1-240-415-6038 [email protected]

Sponsors

Lead Sponsor

Biological Dynamics

Age

21 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Non-small cell lung: Male or Female Adult patient \>= 21 years old
•Breast only: Female Adult patient \>= 21 years old
•Previously diagnosed with one of the following cancers:
•Breast or Non-small Cell Lung
•Cancer has progressed to at least Stage III or higher for lung cancer or,
•Cancer has progressed to stage IV (metastatic) breast cancer
•Participating in standard of care cancer therapy requiring frequent treatments, typically intravenous chemotherapy visits (or as determined by the standard of care for the particular cancer assessed), of a minimum of three (3) treatment visits planned in 9 months from date of enrollment where a clinical assessment will be conducted

Exclusion Criteria

•Physician assessment that obtaining two extra whole blood specimens with minimum volume of 5 mL per treatment visit is contraindicated
•Stage I and II Non-small Cell Lung Cancer
•Stage I through III breast cancer
•Pregnant or planning to become pregnant during the course of the study
•Unable to obtain informed consent from subject or their legal representative
•Life expectancy is less than 9 months
•Presence of one or more of the following other chronic diseases
•Another type of cancer except for non-melanomatous skin tumors
•Autoimmune disease requiring DMARDS or Biologics
•Infectious disease requiring prolonged intravenous antibiotics or hospitalization
•Renal disease specifically those in End Stage Renal Failure
•Recent (\< 3 weeks) major trauma or major surgical procedure(s) or radiation therapy prior to enrollment in the study
•Recent (\< 2 months) major occlusive arterial event such as MI or CVA prior to enrollment in the study

Related studies

RECRUITINGPhase 1/2

A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer

NCT06380816 · Advanced Solid Tumours, Squamous Cell Carcinoma of Head and Neck, and more

RECRUITINGPhase 2

A Study of BMS-986504 in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9)

NCT06855771 · Carcinoma, Non-Small-Cell Lung

RECRUITINGNA

Effects of a Telerehabilitation Intervention in the Management of Complications After Breast Cancer Surgery

NCT06608446 · Breast Neoplasms

RECRUITINGPhase 3

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT07222566 · Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, and more

RECRUITINGPhase 3

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

NCT06758401 · Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, and more

View all related studies →

TR(ACE) Assay Clinical Specimen Study

What this study is about

Save this trial guide to your notes

Contacts

Sponsors

Related studies

A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer

A Study of BMS-986504 in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9)

Effects of a Telerehabilitation Intervention in the Management of Complications After Breast Cancer Surgery

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

Trial snapshot

Condition

Locations shown

For caregivers